Display options
Cite
Seneviratne CJ, Rajan S, Wong SS, et al. Antifungal Susceptibility in Serum and Virulence Determinants of Candida Bloodstream Isolates from Hong Kong. Front Microbiol. 2016;7:216doi: 10.3389/fmicb.2016.00216.
Seneviratne, C. J., Rajan, S., Wong, S. S., Tsang, D. N., Lai, C. K., Samaranayake, L. P., & Jin, L. (2016). Antifungal Susceptibility in Serum and Virulence Determinants of Candida Bloodstream Isolates from Hong Kong. Frontiers in microbiology, 7216. https://doi.org/10.3389/fmicb.2016.00216
Seneviratne, Chaminda J, et al. "Antifungal Susceptibility in Serum and Virulence Determinants of Candida Bloodstream Isolates from Hong Kong." Frontiers in microbiology vol. 7 (2016): 216. doi: https://doi.org/10.3389/fmicb.2016.00216
Seneviratne CJ, Rajan S, Wong SS, Tsang DN, Lai CK, Samaranayake LP, Jin L. Antifungal Susceptibility in Serum and Virulence Determinants of Candida Bloodstream Isolates from Hong Kong. Front Microbiol. 2016 Feb 26;7:216. doi: 10.3389/fmicb.2016.00216. eCollection 2016. PMID: 26955369; PMCID: PMC4767892.
Copy Download .nbib Format: NLM
Share it on

Front Microbiol. 2016 Feb 26;7:216. doi: 10.3389/fmicb.2016.00216. eCollection 2016.

Antifungal Susceptibility in Serum and Virulence Determinants of Candida Bloodstream Isolates from Hong Kong.

Frontiers in microbiology

Chaminda J Seneviratne, Suhasini Rajan, Sarah S W Wong, Dominic N C Tsang, Christopher K C Lai, Lakshman P Samaranayake, Lijian Jin

Affiliations

  1. Oral Sciences, Faculty of Dentistry, National University of SingaporeSingapore; Faculty of Dentistry, The University of Hong KongHong Kong, China.
  2. Faculty of Dentistry, The University of Hong Kong Hong Kong, China.
  3. Department of Pathology, Queen Elizabeth Hospital Hong Kong, China.
  4. Faculty of Dentistry, The University of Hong KongHong Kong, China; School of Dentistry, University of QueenslandBrisbane, QLD, Australia.

PMID: 26955369 PMCID: PMC4767892 DOI: 10.3389/fmicb.2016.00216

Abstract

Candida bloodstream infections (CBI) are one of the most common nosocomial infections globally, and they account for a high mortality rate. The increasing global prevalence of drug-resistant Candida strains has also been posing a challenge to clinicians. In this study, we comprehensively evaluated the biofilm formation and production of hemolysin and proteinase of 63 CBI isolates derived from a hospital setting in Hong Kong as well as their antifungal susceptibility both in the presence and in the absence of human serum, using standard methodology. Candida albicans was the predominant species among the 63 CBI isolates collected, and non-albicans Candida species accounted for approximately one third of the isolates (36.5%). Of them, Candida tropicalis was the most common non-albicans Candida species. A high proportion (31.7%) of the CBI isolates (40% of C. albicans isolates, 10% of C. tropicalis isolates, 11% of C. parapsilosis isolates, and 100% of C. glabrata isolates) were found to be resistant to fluconazole. One of the isolates (C. tropicalis) was resistant to amphotericin B. A rising prevalence of drug-resistance CBI isolates in Hong Kong was observed with reference to a previous study. Notably, all non-albicans Candida species, showed increased hemolytic activity relative to C. albicans, whilst C. albicans, C. tropicalis, and C. parapsilosis exhibited proteinase activities. Majority of the isolates were capable of forming mature biofilms. Interestingly, the presence of serum distorted the yeast sensitivity to fluconazole, but not amphotericin B. Taken together, our findings demonstrate that CBI isolates of Candida have the potential to express to varying extent their virulence attributes (e.g., biofilm formation, hemolysin production, and proteinase activity) and these, together with perturbations in their antifungal sensitivity in the presence of serum, may contribute to treatment complication in candidemia. The effect of serum on antifungal activity warrants further investigations, as it has direct clinical relevance to the treatment outcome in subjects with candidemia.

Keywords: Candida; antifungal susceptibility; clinical isolates; plasma protein binding; virulence factors

References

  1. Med Mycol. 2013 Jan;51(1):1-16 - PubMed
  2. Curr Microbiol. 2010 Dec;61(6):534-40 - PubMed
  3. J Med Microbiol. 1996 Apr;44(4):311-6 - PubMed
  4. Can J Infect Dis Med Microbiol. 2009 Summer;20(2):45-50 - PubMed
  5. Indian J Med Microbiol. 2006 Jul;24(3):186-94 - PubMed
  6. Nat Rev Microbiol. 2004 Dec;2(12):946-53 - PubMed
  7. Eur J Clin Microbiol Infect Dis. 2012 Jan;31(1):21-31 - PubMed
  8. Med Mycol. 2011 Jul;49(5):556-60 - PubMed
  9. Hong Kong Med J. 2009 Aug;15(4):255-61 - PubMed
  10. Int J Antimicrob Agents. 2011 Jul;38(1):65-9 - PubMed
  11. Int J Infect Dis. 2010 Nov;14(11):e954-66 - PubMed
  12. Am J Med Sci. 1978 Jul-Aug;276(1):77-92 - PubMed
  13. J Clin Microbiol. 2001 Sep;39(9):3254-9 - PubMed
  14. Antimicrob Agents Chemother. 2008 Sep;52(9):3259-66 - PubMed
  15. Antimicrob Agents Chemother. 2013 Apr;57(4):1625-31 - PubMed
  16. Ann Lab Med. 2012 Nov;32(6):426-8 - PubMed
  17. Trends Microbiol. 2003 Jan;11(1):30-6 - PubMed
  18. Clin Microbiol Infect. 2010 Nov;16(11):1676-82 - PubMed
  19. J Infect Dev Ctries. 2013 Sep 16;7(9):670-5 - PubMed
  20. J Pathog. 2014;2014:142864 - PubMed
  21. Oral Dis. 2008 Oct;14(7):582-90 - PubMed
  22. J Clin Microbiol. 2002 Apr;40(4):1244-8 - PubMed
  23. Clin Infect Dis. 2008 Jan 1;46(1):120-8 - PubMed
  24. Sabouraudia. 1965 Oct;4(3):187-93 - PubMed
  25. J Clin Microbiol. 1996 Mar;34(3):615-21 - PubMed
  26. Antimicrob Agents Chemother. 2001 Sep;45(9):2475-9 - PubMed
  27. Infect Immun. 2010 Nov;78(11):4839-49 - PubMed
  28. Antimicrob Agents Chemother. 2001 Jul;45(7):2018-22 - PubMed
  29. Am J Med. 1996 Aug;101(2):170-6 - PubMed
  30. Antimicrob Agents Chemother. 2007 May;51(5):1616-20 - PubMed
  31. Trends Microbiol. 2001 Jul;9(7):327-35 - PubMed
  32. Infect Control Hosp Epidemiol. 1997 May;18(5):369-75 - PubMed
  33. Mycoses. 2005 Nov;48(6):365-77 - PubMed
  34. Clin Microbiol Rev. 2007 Jan;20(1):133-63 - PubMed
  35. Antimicrob Agents Chemother. 1985 Nov;28(5):648-53 - PubMed
  36. Antimicrob Agents Chemother. 2011 Jul;55(7):3067-74 - PubMed
  37. Clin Infect Dis. 2004 Aug 1;39(3):309-17 - PubMed
  38. Scand J Infect Dis. 2008;40(5):414-9 - PubMed
  39. Nihon Ishinkin Gakkai Zasshi. 2007;48(1):1-12 - PubMed
  40. Microbiol Mol Biol Rev. 2003 Sep;67(3):400-28, table of contents - PubMed
  41. BMC Bioinformatics. 2015 Aug 26;16:270 - PubMed
  42. PLoS One. 2012;7(3):e33705 - PubMed
  43. J Antimicrob Chemother. 2006 Feb;57(2):288-93 - PubMed
  44. FEMS Microbiol Rev. 2012 Mar;36(2):288-305 - PubMed
  45. Clin Microbiol Infect. 2013 Aug;19(8):E343-53 - PubMed
  46. Infect Control Hosp Epidemiol. 2013 Jan;34(1):1-14 - PubMed
  47. Antimicrob Agents Chemother. 2002 Mar;46(3):834-40 - PubMed
  48. Infect Control Hosp Epidemiol. 2008 Nov;29(11):996-1011 - PubMed
  49. Mycopathologia. 2011 Nov;172(5):389-95 - PubMed
  50. J Clin Microbiol. 2001 Aug;39(8):2971-4 - PubMed
  51. J Hosp Infect. 2011 May;78(1):50-3 - PubMed
  52. Value Health. 2002 Jan-Feb;5(1):26-34 - PubMed
  53. J Clin Microbiol. 1994 Aug;32(8):1923-9 - PubMed
  54. Nat Rev Microbiol. 2004 Apr;2(4):289-300 - PubMed

Publication Types